New shingles vaccine shows promise in Mid-Stage trial

NCT ID NCT07481604

First seen Apr 04, 2026 · Last updated May 17, 2026 · Updated 6 times

Summary

This study tests a new shingles vaccine in 135 healthy adults aged 50 and older. Researchers will compare the immune response and safety of the new vaccine against an existing one to find the best dose. The goal is to prevent shingles, a painful rash caused by the chickenpox virus.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HERPES ZOSTER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CHA Bundang Medical Center

    Seongnam-si, Gyeonggi-do, South Korea

    Contact

  • Chung-Ang University Hospital

    Seoul, Seoul, South Korea

    Contact

  • Ewha Womans University Seoul Hospital

    Seoul, Seoul, South Korea

    Contact

  • Jeonbuk National University Hospital

    Jeonju, Jeollabuk-do, South Korea

    Contact

  • Kyungpook National University Chilgok Hospital

    Daegu, Daegu, South Korea

    Contact

  • The Catholic University of Korea Eunpyeong St. Mary's Hospital

    Seoul, Seoul, 03312, South Korea

    Contact

  • Yongin Severance Hospital, Yonsei University Health System

    Yongin, Gyeonggi-do, South Korea

    Contact

Conditions

Explore the condition pages connected to this study.